Clinical trials: Urothelial Carcinoma of the Urinary Bladder
Urologic Diseases, Hematuria
A Study of Ward Admissions for Haematuria
This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus…
- Conditions
- Urologic Diseases, Hematuria, Hematuria; Benign, Bladder Cancer
- Trial name
- WASHOUT (NCT07395037)
- Testing
- Inpatient work-up and management
- Where
- United Kingdom
- Volunteers
- 1,050 people
- Sponsor
- British Urology Researchers in Surgical Training
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Bladder Cancer, Kidney Cancer
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Bladder Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00016237
- Testing
- tucotuzumab celmoleukin
- Where
- 2 sites in United States
- Sponsor
- EMD Serono
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have metastatic…
- Trial name
- NCT00004203
- Testing
- oxaliplatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has…
- Conditions
- Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT00942331
- Testing
- Bevacizumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- 873 sites in United States, Puerto Rico
- Volunteers
- 506 people
- Sponsor
- National Cancer Institute (NCI)
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence, Progression of Bladder Cancer, Transurethral Resection of Bladder Tumor
- Trial name
- NCT07589413
- Testing
- Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhiping Wang
Muscle-Invasive Bladder Cancer (MIBC)
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin.
- Trial name
- NCT07647289
- Testing
- enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University Third Hospital
Bladder Cancer, Kidney Cancer
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00900276
- Testing
- immunologic technique, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Urothelial Carcinoma Bladder, Bladder Cancer
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-naïve patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- GEMDOCE (NCT04386746)
- Testing
- Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
This phase IV trial tests the impact of standard of care enfortumab vedotin and pembrolizumab followed by removal of all or part of the bladder (cytoreductive cystectomy) and/or removal of all or part of the tube that carriers…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
- Trial name
- NCT06764095
- Testing
- Biospecimen Collection, Computed Tomography, Cystectomy
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Urinary Bladder Neoplasm
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
The study aims to establish the safety and toxicity of a combined intravesical mitomycin C with BCG for patients with bladder cancer.
- Trial name
- NCT02311101
- Testing
- Mitomycin C
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metastatic Urothelial Carcinoma, Urothelial Carcinoma
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced)…
- Conditions
- Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer
- Trial name
- NCT07217496
- Testing
- Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
This Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- ENVISION (NCT05243550)
- Testing
- UGN-102
- Where
- 65 sites in United States, Austria and 8 more
- Volunteers
- 240 people
- Sponsor
- UroGen Pharma Ltd.
Infiltrating Bladder Urothelial Carcinoma
A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer
If radical cystectomy remains the standard of care for muscle invasive bladder cancer, consequences of this surgical procedure are often harsh.
- Trial name
- GETUGV04 (NCT01495676)
- Testing
- Radiation + cisplatin, Radiation + cisplatin + gemcitabine
- Where
- 12 sites in France
- Volunteers
- 69 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
This phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to the lymph nodes.
- Trial name
- NCT04216290
- Testing
- Biopsy of Bladder, Biospecimen Collection, Cisplatin
- Where
- 216 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation
This is a prospective, open, single center clinical study of vidicizumab combined with local radiotherapy as bladder conserving therapy in patients with muscle invasive bladder urothelium cancer with HER-2 expression (IHC 2+or…
- Trial name
- NCT05912205
- Testing
- Disitamab Vedotin, radiotherapy
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
This clinical trial compares how well a home-based personalized physical activity program (PAP) that is delivered by a digital application (app) (the ExerciseRx app) works compared to health education in improving physical…
- Conditions
- Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- EMPOWER (NCT07302230)
- Testing
- Internet-Based Intervention, Best Practice, Exercise Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Washington
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called pembrolizumab versus pembrolizumab alone in treating patients with urothelial cancer that has spread from where it first started…
- Conditions
- Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT04936230
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 83 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Urothelial Carcinoma
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
SURE-01 is a neoadjuvant phase 2, open-label, non-randomized, singlecohort study in patients with urothelial carcinoma of the bladder. Patients will be consecutively enrolled and treated.
- Trial name
- NCT05226117
- Testing
- Sacituzumab govitecan
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- IRCCS San Raffaele